Research programme: G protein-coupled receptor 35 antagonists - ThirtyFiveBio
Latest Information Update: 24 Apr 2025
At a glance
- Originator ThirtyFiveBio
- Class Antineoplastics; Small molecules
- Mechanism of Action GPR35 protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Gastrointestinal disorders
Most Recent Events
- 15 Apr 2025 ThirtyFiveBio plans first-in-human clinical trials in gastrointestinal disorders
- 14 Apr 2023 Pharmacodynamics data from a preclinical study in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 31 Mar 2023 Preclinical trials in Cancer in United Kingdom (unspecified route)